ULURU Announces Approval to Market Altrazeal in New Zealand

ULURU Inc.

, announced today that Altrazeal® has been approved for marketing in New Zealand. Commenting on the approval in New Zealand, Kerry P. Gray, President and CEO of ULURU, stated, "The approval for New Zealand is very timely as the Australian Wound Management Association Conference is currently being held in Sydney. At this conference key opinion leaders from both Australia and New Zealand are being introduced to Altrazeal®. To support the launch of Altrazeal® in Australia and New Zealand a five center, 60 patient study, has been initiated in Australia. A second 90 patient comparative study is planned to be conducted in Europe. This study is to support reimbursement submissions by demonstrating pharmacoeconomic benefits. These two studies will provide additional support for our global marketing activities." With the New Zealand approval it is now anticipated that Altrazeal® will be launched in the near future in six additional markets for human and veterinary use.